MaaT Pharma Announces Positive Topline Results

MaaT Pharma has recently announced positive topline results from its latest studies, marking a significant milestone in its development pipeline. The company is now anticipating the submission of a Marketing Authorization Application (MAA) in Europe by mid-2025, which is earlier than initially planned. This advancement underscores the company's commitment to accelerating the availability of its innovative treatments to patients in need.

In light of these developments, MaaT Pharma has scheduled a conference call and webcast for Thursday, January 9, 2025, at 4.00 PM CET / 7.00 AM PST / 10.00 AM EST / 7.00 PM GST. This event will provide an opportunity for stakeholders and interested parties to gain further insights into the results and the company's future plans.